Efficacy and safety of cadonilimab (PD-1/CTLA-4 bispecific) in combination with chemotherapy in anti-PD-1-resistant recurrent or metastatic nasopharyngeal carcinoma: a single-arm, open-label, phase 2 trial
卡多尼利单抗(PD-1/CTLA-4双特异性抗体)联合化疗治疗抗PD-1耐药的复发性或转移性鼻咽癌的疗效和安全性:一项单臂、开放标签的II期试验
期刊:BMC Medicine
影响因子:8.3
doi:10.1186/s12916-025-03985-4
Jiang, Yaofei; Bei, Weixin; Wang, Lin; Lu, Nian; Xu, Cheng; Liang, Hu; Ke, Liangru; Ye, Yanfang; He, Shuiqing; Dong, Shuhui; Liu, Qin; Zhang, Chuanrun; Wang, Xuguang; Xia, Weixiong; Zhao, Chong; Huang, Ying; Xiang, Yanqun; Liu, Guoying